MDACC Study No:2012-1143 ( NCT No: NCT01891981)
Title:Phase I/II Study of Moxetumomab Pasudotox in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Moxetumomab
Study Status:Closed
Study Description:The goal of this clinical research study is to find the highest tolerable dose
moxetumomab pasudotox that can be given to patients with relapsed and/or
refractory ALL.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Moxetumomab
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:MedImmune Corporation
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
For Clinical Trial Enrollment:713-792-7305
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults